StreetAlpha.app
Home › Stocks › LYEL

Lyell Immunopharma, Inc. (LYEL)

Healthcare
$13.67
▼ −6.69%
LAST CLOSE · NOV 17

Lyell Immunopharma develops engineered immune cell therapies for patients with cancer. It last closed at $13.67 on Nov 17, down 6.69% on the day.

AI Auto Pilots
Is LYEL in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$15K
−63.4% vs a year ago
Net income
−$255.2M
−1701066.7% margin
EPS (diluted)
−$12.61
Free cash flow
−$140.0M
−933100.0% margin
Valuation
Market cap
$336.1M
24.6M shares
P/E
–
No P/E while losing money
Price to sales
22405.6
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$92.1M
At Sep 30
Shareholder equity
$192.7M
Shares outstanding
24.6M
At Oct 30
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $10.7M$10.7MFY2021FY2022: $84.7M$84.7MFY2022FY2023: $130K$130KFY2023FY2024: $61K$61KFY2024FY2025: $36K$36KFY2025

From LYEL's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 4). Last 12 months adds up the four latest quarters.

Next report
—
No date on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated LYEL in the past 90 days, not enough for a consensus
Average 12-month target
$39.00
▲ 185.3% upside

Based on 1 analyst who set a price target on LYEL in the past 90 days. The average target is $39.00, with a high of $39.00 and a low of $39.00, compared with the last close of $13.67.

Low $39.00Avg $39.00High $39.00
Blue marker: last close $13.67
Highest target$39.00
Average target$39.00
Lowest target$39.00
Latest rating changes
HC Wainwright & Co.Target lowered
Nov 13Buy$45 → $39
StifelInitiated
Aug 6Buy$36
B. Riley SecuritiesInitiated
Jul 22Buy$44
HC Wainwright & Co.Reiterated
Jun 9Buy$45
NeedhamReiterated
Jun 8Buy$44
DateFirmActionRatingPrice target
Nov 13HC Wainwright & Co.Target loweredBuy$45 → $39
Aug 6StifelInitiatedBuy$36
Jul 22B. Riley SecuritiesInitiatedBuy$44
Jun 9HC Wainwright & Co.ReiteratedBuy$45
Jun 8NeedhamReiteratedBuy$44
Loading…

Technical Analysis

LYEL · as of the Nov 17 close · updated after every close
Bounce inside a longer downtrend

The stock is 7% above its 20 day and 20% above its 50 day average. It is 19% below its 200 day average, so the longer trend is down. Momentum is strong (RSI 55). The nearest support is the swing low (Aug 17) at $13.39, and the nearest resistance the Pivot at $13.98.

Short trendBullish
Long trendBearish
MomentumStrong
StretchNormal
VolatilityHigh, 9.9%/day
Key levels
$45.0052 week high+229.2%
$16.27200 day average+19.0%
$14.69Pivot R1+7.5%
$14.14Swing high (Jun 11)+3.4%
$13.98Pivot+2.3%
$13.67Last close
$13.39Swing low (Aug 17)−2.0%
$12.95Pivot S1−5.3%
$12.7620 day average−6.7%
$12.54100 day average−8.3%
$10.9950 day average−19.6%
$7.2052 week low−47.3%
Indicators
RSI (14)55.14Middle of its rangeNeutral
MACD1.33Above its signal lineBullish
Stochastic55.6Middle of its rangeNeutral
ADX (14)41.3Strong uptrend
Williams %R-55.8Oversold below −80, overbought above −20Neutral
CCI (20)31.5Oversold below −100, overbought above 100Neutral
Rate of change+26.9%Change over 10 sessionsBullish
ATR (14)$1.36Typical daily range, 9.9% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Below
What happened before, for LYEL

What happened before

See how LYEL did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow LYEL usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How LYEL has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in LYEL in the last 90 days.

Loading…

See today’s whale options flow across the market →

LYEL Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲64 buying vs 33 selling
  • ●Held by funds +0.4 pts
  • ▲Funds holding +18
  • ▲Superinvestors: 3 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10587+20.7%
In funds' top 1047−42.9%
Held by funds52.0%51.6%+0.4 pts
New / increased28 / 3623 / 28+25.5%
Reduced / sold out23 / 1019 / 9+17.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LYEL institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LYEL is in one of them and how their past LYEL trades turned out.

LYEL in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LYEL in an article yet. Here's the latest on the wider market.

About Lyell Immunopharma

Lyell Immunopharma is a clinical stage biotechnology company that develops cell therapies for patients with cancer. It takes immune cells from each patient and engineers them to better find and destroy cancer cells. Its lead candidate, rondecabtagene autoleucel, is being studied in patients with large B cell lymphoma, and the company is also developing LYL273 for advanced colorectal cancer. The company is based in South San Francisco, California.

Headquarters
South San Francisco, CA